Drugs / Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments
Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04514302 | Dec 2021 → Aug 2022 | COVID-19 | TecSalud Investigación Clínica | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-SARS-CoV-2 equine immunoglobulin F(ab')2 fragments | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04514302 ↗ |
| Modality | Protein / enzyme biologic | “anti-SARS-CoV-2 immunoglobulin F(ab')2 fragments” NCT04514302 ↗ |
| Route | Intravenous | “administered intravenously as an infusion” NCT04514302 ↗ |